NCT06786312

A Single-arm, Multicenter, Prospective Phase II Clinical Study of Apatinib in Combination With Adebrelimab and EC Regimen in the First-line Treatment of Extensive Small Cell Lung Cancer

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 34 (estimated)
• Sponsor: Fujian Cancer Hospital · Other Government
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the efficacy and safety of apatinib combined with adebrelizumab and EC in the first-line treatment of extensive small cell lung cancer

Conditions

• Small Cell Lung Cancer Extensive Stage

Interventions

Type	Name	Description
DRUG	Apatinib	250mg, P.O, qd, 21 days per cycle;
DRUG	Adebrelimab	20mg/kg or 1200mg ivgtt, d1, 21 days per cycle;
DRUG	Etoposide Injection	100mg/m\^2 ivgtt for the first, second and third consecutive days, 21 days per cycle.
DRUG	Carboplatin Injection	Day 1 administration, AUC=5, intravenous infusion; One treatment cycle every 21 days.

Timeline

• Start date: 2025-01-25
• Primary completion: 2027-07-25
• Completion: 2028-09-25
• First posted: 2025-01-22
• Last updated: 2025-01-22

Locations

4 sites across 1 country: China